For research and educational purposes only. Not medical advice.

Amycretin Reference

Educational, not medical advice reference for Amycretin: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes…

Plain English

What it is
Amycretin is an experimental obesity medicine from Novo Nordisk. It is a single molecule that switches on two of the body's appetite signals at once: the GLP-1 pathway (the same one used by Ozempic and Wegovy) and a second one called amylin. It is being tested as both a pill and a shot.
What people use it for
It is being studied to help adults with overweight or obesity lose weight, and separately to help manage type 2 diabetes. Right now it is used only inside clinical trials, not by the general public.
What the science shows
In early human studies, people lost a meaningful amount of weight over a few months, and the shot form drove more loss than the pill at the amounts tested. The main side effects were stomach-related, like nausea, and were usually mild to moderate. These were early, small studies focused mostly on safety.
The catch
It is not approved by the FDA or anyone else, and you cannot get it by prescription. The studies so far are small and short, so we do not yet know how well it works or how safe it is over the long run. Anything sold online as amycretin is not the real trial drug and is not tested for safety.

Reference summary

Human evidence is limited to early-phase trials published in The Lancet in 2025. Oral amycretin (144 participants, once-daily tablet, up to 12 weeks) produced mean weight loss up to about 13 percent versus about 1 percent on placebo. Subcutaneous amycretin (125 participants, once-weekly injection) produced mean weight loss of about 10 percent at 20 weeks, about 16 percent at 28 weeks, and about 22 to 24 percent at 36 weeks at the highest maintenance levels, versus roughly flat placebo. The most common adverse events were gastrointestinal (nausea, vomiting) and decreased appetite, mostly mild to moderate, consistent with incretin-based therapies. These are early-phase proof-of-concept findings, not confirmatory efficacy or long-term safety data.

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
NNC0487-0111, NN9487, oral amycretin, subcutaneous amycretin, GLP-1 and amylin receptor agonist
Evidence posture
human - Investigational and not FDA-approved: human data are limited to phase 1 and phase 1b/2a trials, now advancing to phase 3.
Regulatory status
Investigational. Amycretin is a Novo Nordisk unimolecular GLP-1 and amylin receptor agonist (oral and subcutaneous forms). It is NOT FDA-approved, is not approved anywhere, and exists only inside clinical trials. Novo Nordisk announced on 20 June 2025 that both forms are advancing to phase 3 for overweight and obesity, with a separate phase 3 type 2 diabetes program announced later in 2025. There is no approved label and no legal consumer supply.
Content review status
investigational verified

Selected public sources

Related tools